Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2020-11-18
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies whether it is feasible to conduct a detailed molecular
profile of triple negative breast cancer as part of a treatment strategy that asks whether or
not we can lower the chance of breast cancer growing or spreading, by treating with a
combination of PARP inhibitor how well (olaparib) and immune therapy (durvalumab). Olaparib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Giving olaparib and durvalumab may work better in treating participants with
metastatic triple negative breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Oregon Health and Science University Prospect Creek Foundation
Treatments:
Antibodies, Monoclonal Durvalumab Immunoglobulin G Immunoglobulins Olaparib Poly(ADP-ribose) Polymerase Inhibitors